2203 GVHD Prophy-Rux (PROGRESS IV)

Go Back to BMT CTN Protocol Listing

  • Protocol Short Name and Number: 2203 GVHD Prophy-Rux (PROGRESS IV)
  • Protocol Long Name:  A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
  • Protocol (PDF)
  • ICFs (PDF)
  • FAQs (TBD)
  • Key Personnel
    • BMT CTN # 2203 Co-Chair: Elizabeth Hexner, MD
    • BMT CTN # 2203 Co-Chair: Zack DeFilipp
    • BMT CTN # 2203 Protocol Officer: Steven Devine, MD
    • BMT CTN # 2203 Protocol Coordinator: bmtctn2203@emmes.com
  • Keywords: PROGRESS, Graft versus Host Disease, GVHD Prophylaxis, GVHD, Post-Transplant Cyclophosphamide, PTCY, Allogeneic Transplant, Allo Transplant, Allo, Unrelated donor, Unrelated, Hematopoietic Stem Cell Transplant, HSCT, HCT, Tacrolimus, TAC, Tacro, Methotrexate, MTX, Mycophenolate Mofetil, MMF, Acute Leukemia, Chronic Myelogenous Leukemia, CML, Myelodysplastic Syndrome, MDS, Chronic Myelomonocytic Leukemia, CMML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Leukemia, Ruxolitinib